Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Buy” from Analysts

Clearside Biomedical, Inc. (NASDAQ:CLSD) has been assigned a consensus rating of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.60.

Several analysts recently issued reports on the stock. Zacks Investment Research cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. Finally, TheStreet cut shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th.

In other news, Director Gerald D. Cagle purchased 5,000 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $7.08 per share, with a total value of $35,400.00. Following the purchase, the director now directly owns 15,941 shares in the company, valued at approximately $112,862.28. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Clay Thorp sold 4,500 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $8.02, for a total transaction of $36,090.00. The disclosure for this sale can be found here. In the last three months, insiders bought 7,100 shares of company stock valued at $50,170 and sold 132,000 shares valued at $1,053,550. Corporate insiders own 20.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC grew its stake in shares of Clearside Biomedical by 4.0% in the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after buying an additional 563 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Clearside Biomedical by 10.8% in the 1st quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock valued at $277,000 after buying an additional 3,404 shares during the period. Marshall Wace North America L.P. grew its stake in shares of Clearside Biomedical by 1.9% in the 2nd quarter. Marshall Wace North America L.P. now owns 218,960 shares of the company’s stock valued at $1,971,000 after buying an additional 4,010 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of Clearside Biomedical by 30.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after acquiring an additional 4,527 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in shares of Clearside Biomedical by 118.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after acquiring an additional 6,343 shares during the last quarter. 52.45% of the stock is owned by institutional investors and hedge funds.

Clearside Biomedical (NASDAQ:CLSD) opened at 7.81 on Wednesday. The company has a 50-day moving average price of $8.05 and a 200 day moving average price of $8.05. The stock’s market cap is $197.87 million. Clearside Biomedical has a 52-week low of $5.44 and a 52-week high of $24.73.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative net margin of 27,225.52% and a negative return on equity of 65.78%. The business had revenue of $0.13 million for the quarter. On average, analysts expect that Clearside Biomedical will post ($2.10) earnings per share for the current year.

WARNING: “Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Buy” from Analysts” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/18/clearside-biomedical-inc-clsd-receives-average-rating-of-buy-from-analysts.html.

Clearside Biomedical Company Profile

Clearsid

Several analysts recently issued reports on the stock. Zacks Investment Research cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. Finally, TheStreet cut shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th.

In other news, Director Gerald D. Cagle purchased 5,000 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $7.08 per share, with a total value of $35,400.00. Following the purchase, the director now directly owns 15,941 shares in the company, valued at approximately $112,862.28. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Clay Thorp sold 4,500 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $8.02, for a total transaction of $36,090.00. The disclosure for this sale can be found here. In the last three months, insiders bought 7,100 shares of company stock valued at $50,170 and sold 132,000 shares valued at $1,053,550. Corporate insiders own 20.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC grew its stake in shares of Clearside Biomedical by 4.0% in the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after buying an additional 563 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Clearside Biomedical by 10.8% in the 1st quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock valued at $277,000 after buying an additional 3,404 shares during the period. Marshall Wace North America L.P. grew its stake in shares of Clearside Biomedical by 1.9% in the 2nd quarter. Marshall Wace North America L.P. now owns 218,960 shares of the company’s stock valued at $1,971,000 after buying an additional 4,010 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of Clearside Biomedical by 30.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after acquiring an additional 4,527 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in shares of Clearside Biomedical by 118.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after acquiring an additional 6,343 shares during the last quarter. 52.45% of the stock is owned by institutional investors and hedge funds.

Clearside Biomedical (NASDAQ:CLSD) opened at 7.81 on Wednesday. The company has a 50-day moving average price of $8.05 and a 200 day moving average price of $8.05. The stock’s market cap is $197.87 million. Clearside Biomedical has a 52-week low of $5.44 and a 52-week high of $24.73.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative net margin of 27,225.52% and a negative return on equity of 65.78%. The business had revenue of $0.13 million for the quarter. On average, analysts expect that Clearside Biomedical will post ($2.10) earnings per share for the current year.

WARNING: “Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Buy” from Analysts” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/18/clearside-biomedical-inc-clsd-receives-average-rating-of-buy-from-analysts.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply